Newderivatives of spicamycin modified at the fatty acid moieties of the molecule were synthesized and their structure-activity relationships were examined. The antitumor activity was greatly influenced by modification of the fatty acid moieties to tetradecadienoyl or dodecadienoyl analogues exhibiting better antitumor activity against COL-1human colon cancer xenograft than SPMVIII.
Newderivatives of spicamycin modified at the fatty acid moieties of the molecule were synthesized and their structure-activity relationships were examined. The antitumor activity was greatly influenced by modification of the fatty acid moieties to tetradecadienoyl or dodecadienoyl analogues exhibiting better antitumor activity against COL-1human colon cancer xenograft than SPMVIII.
Spicamycin (1)1'2) is an antitumor antibiotic produced by Streptomyces alanosinicus 879-MT3, and is comprised of four moieties; fatty acid, glycine, amino sugar and adenine unit (the structures are given in Fig. 1 ). Spicamycin is a mixture of compoundsconsisting of C12^2o straight and branched fatty acid moieties. The amino sugar moiety was determined to be a heptose, 4-amino-4-deoxy-L-g/jc^r6>-L-ma^7^6>-heptopyranose3), and is linked glycosidically to the 6-amino group of adenine.
Previously, we reported the preparation of several semi-synthetic spicamycin analogues which differed in the length of the fatty acid moieties and examined their in vitro and in vivo structure-activity relationships.4) SPM VIII (2)4), which is a dodecanoyl analogue, showed a potent antitumor activity against humanbreast cancer MX-1 and human stomach cancer SC-9 in the human of SPM VIII against SC-9 was 4-fold higher (T.I.=4) than that ofspicamycin (T.I. = 1). SPM VIII also showed a good antitumor activity against several other human tumor xenografts. 5)
In this paper, wereport the preparation of several new spicamycin analogues and describe their in vivo antitumor activities.
Chemistry
Spicamycin (1) was obtained from the culture broth of Streptomyces alanosinicus 879-MT3 by the method of Hayakawa et al.li2) The amino nucleoside moiety of spicamycin (SAN; 3) was prepared by hydrolysis of spicamycin with 10% HCl-MeOH.4) The 4'-N-glycylated SAN (SAN-Gly; 5) was prepared by removing the BOCgroup after coupling N-(ter/-butoxycarbonyl)glycine to SAN(3). Condensation of appropriate fatty acids with SAN-Gly (5) by the active ester method6) yielded spicamycin derivatives except 22a, 22b, and 22c (Scheme 1). Except for those which were available commercially, fatty acids for the preparation of analogues were synthesized as described in detail in the experimental section. The carbamate analogues (22a, 22b, 22c) were synthesized from 5 and appropriate N-alkoxy carbonyloxy succinimide, which was prepared from appropriate alcohol and N,N'-disuccinimidyl carbonate7) (Scheme 2). The alkylglycylated analogue (23) was synthesized from 5 and dodecanal under reductive animation conditions with NaBH3CN8) (Scheme 3). a) CH3(CH2)10CHO, NaBH3CN, EtOH, rt.
Results and Discussion
Spicamycin analogues were evaluated for in vivo antitumor activities in a human tumor xenograft model,9) in which fragments of tumor (COL-1) were implanted s.c. into athymic nude mice (BALB/c nu/nu Sic, Japan SLC Inc., Shizuoka, Japan). When the tumors had grown to a palpable size (100~300mm3), spicamycin analogues at each dose were given intravenously by daily injection for five days.
The antitumor activity of spicamycin analogues against COL-1 was evaluated by tumor growth inhibition rate (T.G.I.R.) at each dose. The T.I.10) which gives a more realistic representation of the margin between antitumor activity and toxicity of each spicamycin analogues was calculated.
The results are summarized in Figures 2~6 in comparison with those of SPM VIII4) (T.I. =4). Among the derivatives with the modified fatty acid moiety, comethyl substituted (6a~6c) and co-cyclopropyl (7a, 7b) substituted analogues showed almost the same activity as the corresponding linear and saturated fatty acid analogues as shown in our previous report4) (Fig. 2) . The co-halogenated fatty acid analogues 8a exhibited the same T. I. value that of SPM VIII, C12~i4 acids (8b, 8c, 8d, 9b, 9c) derivatives exhibited double T.I. values than that of SPMVIII. (Fig. 3) . The a and co-fluorinated analogues (10, lib) showed a similar activity. The analogues with one hydroxyl group at a, /? or co position exhibited unique structure-activity relationships (Fig. 4) . The mixture of 2-hydroxy diastreoisomers (12a) displayed moderate activity, but hydroxylation of the co-position (14a, 14b) led to a significant reduction in activity.
To further investigate the influence of the chirality at the a-position, conformational isomers (12b, 12c) were prepared. The chiral (2S)-hydroxy analogue (12c) exhibited higher therapeutic index (T.I. =8) than (2R) analogue (12b, T.I. =2). In contrast, (35)-hydroxy (13b) and (3i?)-hydroxy (13a) analogues had a similar therapeutic index (T.I. = 4). These findings suggested that chirality of the a-position is important for high therapeutic index, but that of the^-position does not affect activity. The two carbon elongated 3-hydroxy analogue (13c) had the same activity as that of SPM VIII. On the other hand, some of the co-aryloxy analogues such as those with phenoxy (15a), benzyloxy (15b) and diphenylmethyloxy (15g) at the co-position exhibited a similar potency as SPMVIII, but other analogues possesing naphthyloxy (15i), p-toluenesul- Fragments of COL-1humancolon cancer were implanted subcutaneously into athymic nude mice. Whenthe tumor size reached 100~300mm3,spicamycin derivatives were administered iv daily for five days. Results are expressed as the value of maximum tumor growth inhibition rate (T.G.I.R.) at each dose during the experimental period; five mice per group. Terapeutic index (T.L) = maximumtolerated dose/minimum effective dose. Open circles; toxic (one or more animals died), closed circles; effective (T.G.I.R. > 50), gray circles; ineffective (T.G.I.R. < 50). fonyloxy (15e, 15f), and methoxy (15c) moieties at the co-position were less active. The benzoyloxy analogue (15b) showed a moderate activity. Replacement of the hydroxyl group at the co-position with a hydrophobic subsituent resulted in the retention of the activity, but the bulky and hydrophobic analogue (15h) did not show a sufficient activity (Fig. 4) .
In general, the fatty acid analogues with double bonds exhibited good activities (Fig. 5) . The activities of the analogues with one double bond at the ajS (16a, 16b) or co (17a,17b) position were nearly equal to those of saturated analogues with the corresponding carbon chain length in the fatty acid moiety. The maximumtolerated doses of the unsaturated analogues were generally higher than those of the saturated analogues due to the reduction in the toxicity. The introduction of one triple bond at the a/? (21a, 21b,21c, 21d) or co (20a,20b) position did not appear to alter the activity except in compound21d (Fig. 6) . The analogue consisting of C16 fatty acids with one double bond at 9-position (18) was moderately active (Fig. 5) . In contrast, the saturated C16 fatty acid analogue showed no activities but high toxicity.4) These results indicated that the existence of a double bond at 9-position affected on the conformation of the fatty acid moiety resulting in the appearance of antitumor activity. Among the unsaturated fatty acid analogues, the a/?,y (5-dienoyl derivatives (19a, 19c) showed excellent activities; their therapeutic indices of them (T.L = 16) # Structure was given in Scheme3.
were 4-fold higher than that of SPM VIII (Fig. 5) . As a result of their potent antitumor activities and broad dose ranges of therapeutic effect, these compounds show great potential for further development as useful antitumor agents.
To clarify the influence of the amide bond in spicamycin analogues on the antitumor activities, we synthesized the carbamate analogues (22a, 22b,22c) and evaluated their activities (Fig. 6 ). Interestingly, these analogues did not lose their activities, suggesting that the amide bond is not essential for activity and can be replaced by a carbamate bond. On the other hand, the alkyl analogues of the amino group in the glycine moiety (23) showed no activity. From the above results it was suggested that the glycine moiety has an important role in the expression of the antitumor activity. Previously,1 1} we speculated the spicamycin is metabolized by an intracellular enzyme to SAN-Gly (5) which inhibits the protein synthesis in tumor cells. The importance of the glycine moiety substantiated in this structure-activity relationship study is consistent with the evidence from the biochemical experiments concerning SAN-Gly. In this study, the hydrophobicity of the fatty acid moiety had a large effect on in vivo antitumor activity, which could be explained by the permeability of spicamycin derivatives into tumor cells. Similar results were reported previously for N-acyl derivatives of Ara-C.12) The fatty acid moiety of N-acyl derivatives of Ara-C played an important role in the introduction of the compoundinto cancer cells. Furthermore, we are interested in the substrate specificity of the intracellular enzyme, since 2-chiral hydroxyl analogues (12b, 12c) exhibited different activities despite having the same hydrophobicity.
Further studies regarding the mode of action of spicamycin derivatives are now in progress in our laboratory.
Experimental
General All Mp's were obtained with Yanagimoto melting point apparatus and uncorrected. IR spectra were measured on a Jasco A-3 spectrophotometer. XHNMR spectra were recorded with a JEOLGX-500spectrometer with tetramethylsilane as an internal standard. The FD mass spectra were obtained with a Hitachi M80mass spectrometer. Optical rotations were measured on a JASCODIP-140 spectropolarimeter.
Silica gel column chromatography was performed on Wakogel C-200 manufactured by Wako Pure Chemical Industries, Ltd.
of4.00g of1 in 36ml of 10% HC1-MeOH was refluxed for 4hours and cooled to 20°C. EtOAc (50ml) was added to the reaction mixture, the resulting precipitate was collected by filtration, and washed with EtOAc (20 ml). This precipitate was dissloved in water, and bacified with ammoniawater to pH 7.5. The resulting precipitate was filtered and dried under reduced pressure. This white powderwas suspended in 4ml water, and acidified with 1 n HC1solution to pH 1. Activated charcol (4g) was added to the mixture. After filtration of the mixture, and filter cake was washed with diluted HC1 solution (3ml, pH 3). The filtrate was basified with ammonia water to pH 7.5, and stirred for 30minutes at 25°C. The resulting precipitate was collected by filtration, and washed with water (2ml). After drying, these pricipitates was suspended with MeOH(10ml), and stirred for 3hours at 25°C. This mixture was filtered, and filter cake was dried under reduced pressure to give (2) [a]£5= +20.4°(c 0.1, MeOH). mp 189~190°C. 
(1H, s), 8.28 (1H, s). FD-MS 384 (M++H).
[a]£5= +3.6°(c 0.25, MeOH-H2O). mp 195~198°C.
The typical procedure for the introduction of side chains; the synthesis
To a mixture of 10-methylundecanoic acid (240mg, 1.20mmol) and p-nitrophenol (167mg, 1.20mmol) in DMF(30 ml) was added N,N-dicyclohexylcarbodiimide (DCC) (247mg, 1.20mmol) at room temperature. The reaction mixture was stirred at the sametemperature for 12hours and filtered. To the filtrate were added 5 (460mg, 1.10mmol) and triethylamine (2.0ml), and the mixture was stirred at the room temperature for 12 hours. After evaporation, the residue was purified by (6b)- (21d) were also synthesized from 5 in the same sequence of reaction for the synthesis of 6a using the corresponding carboxylic acid.
This compound was obtained from 5 and 1 1-methyldodecanoic acid in the typical procedure. Yield 24.0%. IRvmax (KBr) 3300, 1620cm" [a]£5= +2.8°(c O.l, MeOH). mp 170-171°C. [a]is5= +9.1°(c 0.1, MeOH). mp 225-226°C. 
This compound was obtained from 5 and ll-bromoundecanoic acid in the typical procedure. Yield 31.1%.
IRvmax (KBr) 3400, 1630cm"1. XH NMR (CD3OD) dH [a]g5= +17.3°(c 0.1, MeOH). mp 175~.178°C.
This compound was obtained from 5 and 12-bromododecanoic acid in the typical procedure. Yield 22.7%. IRvmax (KBr) 3400, 1630cm"1. *H NMR (CD3OD) 5H 
This compound was obtained from 5 and 14-bromotetradecanoic acid in the typical procedure. Yield 27.3%. IRvmax (KBr) 3400, 1630cm-1. XH NMR (CD3OD) 8H 
This compound was obtained from 5 and 14-chlorotetradecanoic acid in the typical procedure. Yield 33.0%. IRvmax (KBr) 3300, 1630cm"1. XH NMR (CD3OD) <5H 
(1H, s). FD-MS 639 (M++H).
[a]js5=-14.4°(c 0.1, MeOH). mp 173~174°C.
This compound was obtained from 5 and (3i?)-hydroxytetradecanoic acid in the typical procedure. Yield 9.7%. IRvmax (KBr) 3300, 1630cm"1.
XH NMR benzyloxydecanoate was added to the mixture, and the reaction mixture was stirred at 70°C for 1 hour. After the reaction mixture was cooled, and it was adjusted to the weak acidic range of pH with citric acid and extracted with EtOAc. The organic layer was dried over [a]£5= +13.2°(c 0.1, MeOH). mp 202~204°C. mp 201~203°C.
12-hydroxydodecanoic acid (1.0 g, 3.77 mmol) was dissolved in a mixed solvent of 10% HCl-MeOH-CH2C12 (5 : 1) (25ml), and the mixture was stirred at room temperature for 1 hour. [a]^5=-1.2°(c 0.1, MeOH). Japan) were used. The animals were kept under specific pathogen free conditions using laminar air flow racks and were fed sterile food and water ad libitum.
Human colon cancer COL-1 were kindly supplied by the Central Institute for Experimental Animals, Kanagawa, Japan, and maintained in athymic nude mice. Chemotherapeutic experiments were performed as described by Inaba et al. Fragments of xenografts were implanted sc into the right subaxillary region of athymic nude mice. When the tumors had grown to a palpable size (100~300mm3), the mice were randomly allocated to several experimental groups consisting of five animals each and spicamycin derivatives at each dose were given was determined as follows; T.G.I.R.=(1 -T/C) x 100 where T is the mean of RVin treated mice and C is the mean of RVin control mice. Evaluation as "effective" was based on the maximum T.G.I.R. (%) for an experimental span of 50% or more showing ststistical significance as determined by the Mann-Whitney's U-test (P<0.05, one sided). A toxic dose was difined as one causing the death of one or more mice in a group. The T.I. was determined as follows; T.I. = maximumtolerated dose/minimum effective dose.
